- Home
- PTGX
as 11-21-2024 4:00pm EST
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | NEWARK |
| Market Cap: | 2.8B | IPO Year: | 2016 |
| Target Price: | $53.57 | AVG Volume (30 days): | 700.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.80 - $48.89 | Next Earning Date: | 11-07-2024 |
| Revenue: | $323,795,000 | Revenue Growth: | 125.73% |
| Revenue Growth (this year): | 396.93% | Revenue Growth (next year): | -45.02% |
Stock Insider Trading Activity of Protagonist Therapeutics Inc. (PTGX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ali Asif | PTGX | Chief Financial Officer | Sep 11 '24 | Sell | $44.53 | 14,203 | $631,871.77 | 34,960 | |
| Waddill William D. | PTGX | Director | Sep 10 '24 | Sell | $45.00 | 8,000 | $360,000.00 | 12,000 |
Latest Protagonist Therapeutics Inc. News
PTGX Breaking Stock News: Dive into PTGX Ticker-Specific Updates for Smart Investing
ACCESSWIRE
2 days ago
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
ACCESSWIRE
3 days ago
Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor
Zacks
8 days ago
Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know
Argus Research
9 days ago
PTGX: Lowering target price to $45.00
Zacks
14 days ago
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates
Associated Press Finance
14 days ago
Protagonist Therapeutics: Q3 Earnings Snapshot
ACCESSWIRE
14 days ago
Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Argus Research
16 days ago
PTGX: Lowering target price to $48.00
Compare PTGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PTGX Protagonist Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.